OrphoMed to Present at the 2017 BIO Investor Forum

October 16, 2017

SAN FRANCISCO, CA– OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced that Nikhilesh N. Singh, Ph.D., President and Chief Executive Officer, will present at the 16th Annual BIO Investor Forum, being held October 17-18, 2017, in San Francisco.

Date: October 17, 2017

Time: 02:15 – 02:28 p.m. PT

Location: The Westin St. Francis, Yorkshire Room

A copy of the presentation will be available at www.orphomed.com.

About OrphoMed, Inc.

OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics for patients with gastrointestinal disorders. Leveraging its proprietary dimer platform technology, OrphoMed is advancing ORP-101, a potential best-in-class buprenorphine dimer in clinical development for the treatment of IBS-D, and its pipeline of additional dimer conjugates. For more information please visit www.orphomed.com.

CONTACT:
Gregory L. Beyer
(415) 569-4417
glb@orphomed.com